XML 69 R57.htm IDEA: XBRL DOCUMENT v3.22.2
License and Collaboration Agreements - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 29, 2021
Aug. 31, 2020
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2021
Feb. 28, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue     $ 73,746   $ 54,024 $ 75,440   $ 54,486    
Deferred revenue, current portion     7,190     7,190        
Receivable from licensing and collaboration agreements     22,821 $ 19,749 [1]   22,821 $ 19,749 [1]   $ 19,749 [1]  
Research and development     108,400   101,960 216,049   224,519    
ASC 808                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Receivable from licensing and collaboration agreements     15,500 5,900   15,500 5,900   5,900  
Research and development       19,500 2,900   19,500    
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses     200   4,100 1,300   4,100    
License and Collaboration Agreement | BMS                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment yet to be received     90,000     90,000        
Upfront, regulatory and launch milestone payments yet to be received     815,000     815,000        
License and Collaboration Agreement | Helsinn Therapeutics                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Percentage share of global development costs 60.00%                  
License and Collaboration Agreement | Helsinn Therapeutics | License and Services Revenue | ASC 808                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Receivable from licensing and collaboration agreements     600 0   600 0   0  
License and Collaboration Agreement | Helsinn Therapeutics | License and Services Revenue | ASC 606                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue         44,400     44,400    
Receivable from licensing and collaboration agreements     200 10,000   200 10,000   10,000  
License and Collaboration Agreement | QED Therapeutics, Inc                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront, regulatory and launch milestone payments yet to be received $ 100,000                  
License agreement percentage share of profits and losses 50.00%                  
Percentage share of global development costs 40.00%                  
Regulatory and sales-based milestone payments yet to be received                   $ 66,000
License and Collaboration Agreement | QED Therapeutics, Inc | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Milestone payments $ 2,450,000                  
License and Collaboration Agreement | QED Therapeutics, Inc | Helsinn Therapeutics                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Initial transaction price for the license and collaboration agreement 46,000               56,000  
Nonrefundable upfront license fee 20,000                  
Sale of certain existing inventory 1,000                  
Launch milestone payment $ 25,000                  
Increase in initial transaction price for license and collaboration agreement       $ 10,000            
Allocation of transaction price to licenses                 54,400  
Allocation of transaction price to transfer of certain existing inventory             $ 1,600   $ 1,600  
Receivable from licensing and collaboration agreements     12,500     12,500        
Research and development     9,500     $ 12,800        
Reimbursement percentage of research and development costs incurred           100.00%        
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses     400     $ 500        
Reimbursement percentage of commercial activity costs incurred           100.00%        
License and Collaboration Agreement | Navire Pharma, Inc | BMS                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Milestone payments     0     $ 0        
Initial transaction price for the license and collaboration agreement           90,000        
Allocation Of transaction price for research and development           19,800        
Allocation of transaction price to licenses           70,200        
Total revenue     73,400     73,400        
Deferred Revenue     16,600     16,600        
Deferred revenue, current portion     7,200     7,200        
Deferred Revenue Noncurrent     9,400     9,400        
License and Collaboration Agreement | Navire Pharma, Inc | Research and Development Services Performance Obligation | BMS                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue     3,200     3,200        
License and Collaboration Agreement | Receivable from Licensing and Collaboration Agreements [Member] | QED Therapeutics, Inc | Helsinn Therapeutics                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Receivable from licensing and collaboration agreements     4,000     4,000        
License and Collaboration Agreement | Other Noncurrent Assets [Member] | QED Therapeutics, Inc | Helsinn Therapeutics                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Receivable from licensing and collaboration agreements     8,500     8,500        
License Agreement | LianBio                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Nonrefundable upfront payment receivable           8,000        
License Agreement | LianBio | License and Services Revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue     $ 0   $ 8,500 $ 0   $ 8,500    
License Agreement | LianBio | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Future potential development and sales milestone payments yet to receive   $ 382,100                
[1] The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.